Kornimate/medical-research-clean huggingface dataset:
medication review improves pain management and quality of life in chronic pain

Conditions: Chronic Pain

Summary: the goal of this parallel-group, single-blinded, randomized study is to conduct medication review (mr) type iii in chronic non-cancer pain patients to optimize drug therapy and measure it's influence on pain intensity and quality of life in the primary care setting. the study took place in porto, portugal with the collaboration of two primary care units (usf arca d'água and usf campanhã - polo s. roque da lameira) under aces porto oriental, from where patients were recruited. the main question it aims to answer is: * does the implementation of pharmacist-led medication review benefit patients with chronic pain in the primary care setting? * researchers will compare with "usual care" (uc) patients which receives general advice on how to manage their pain and/or recommendations to take "over the counter" drugs, similar to community pharmacy visits, to see if there is a clinically significant difference in pain intensity and quality of life between the two groups of patients. * participants will be asked to attend face-to-face interviews once a month for 4 months with an expert in medication review, that evaluates their current medication and suggests an individualized care plan. these plans include measures aimed at physicians (e.g., medication adding; dose reduction) and participants (e.g., non-pharmacological measures; adherence to medication).


Eligibility criteria:
inclusion criteria: * non-cancer chronic pain (\>3 months, any cause) * follow-up at one of the selected primary care units * average weekly pain score ≥4 at the screening phase * ability to attend monthly in-person or video interviews exclusion criteria: * pregnancy * breastfeeding * dementia * other mental illness impairing self-reporting

Keywords: medication review chronic pain quality of life pharmaceutical care primary care
prostaglandins use before mirena iud insertion in prev cs women during lactational amenorrhea

Conditions: to Study the Estimate Difficulty of Insertion Mirena IUD With Use of Prostaglandins

Summary: this is a prospective randomized controlled study to determine the effect of prostaglandin intake before mirena iud insertion it was conducted at the department of obstetrics \& gynecology, kasr el-ainy teaching hospital, faculty of medicine, cairo university,

the study aiming to measure the estimate difficulty of insertion of the mirena iud by using prostaglandins 2 hours before the procedure and the effect of prostaglandins to make this procedure easy with other side effects and complications as bleeding perforation, nausea, vomiting, failure of insertion and comparing them with a placebo group who didn't receive prostaglandins

Eligibility criteria:
inclusion criteria: * 1- women in lactational amenoeehea with pregnancy test negative 2- women who had caesarean section within 6 monthes of iud insertion 3- no medical disorders exclusion criteria: * 1- women in regular menses 2- medical disorders 3- nulligravida or muligravida with nvd 4- women with history of previous cs more than one cs 5- any congenital uterine anomalies, fibroids and adenomysis 6- chronic pelvic pain 7- intrauterine adhesions 8- spasmodic dysmenohrrea 9- allergy to misoprostol
a long-term registry of humira® (adalimumab) in patients with moderately to severely active ulcerative colitis (uc)

Conditions: Ulcerative Colitis (UC)

Summary: this is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active uc who are treated as recommended in the product label.


Eligibility criteria:
inclusion criteria: * for enrollment into the humira treatment group; adult patients with moderately to severely active uc who has been prescribed humira therapy according to routine clinical practice and meets one of the following: 1. is currently taking humira therapy and has received at least 8 weeks of therapy; or 2. is entering after participation in an abbott or abbvie sponsored uc study and; has received continuous humira therapy since initiation of therapy * for enrollment into the imm treatment group; adult patients with moderately to severely active uc who has been prescribed imm therapy, is currently taking imm therapy, and has received at least 12 consecutive weeks of imm therapy * patients capable of and willing to grant authorization for use/disclosure of data being collected and provided to abbvie prior to any registry-related data being collected, and to comply with the requirements of the registry protocol exclusion criteria: * patients on imm therapy without a concurrent biologic if they cannot continue to be treated with imm therapy or * patients who are being treated with any investigational agents and/or approved biologics other than humira.

Keywords: ulcerative colitis registry adalimumab colitis gastroenteritis inflammatory bowel diseases gastrointestinal diseases
neuropathic pain and postural stability in patients with lumbar radiculopathy

Conditions: Postural Stability; Balance; Distorted; Neuropathic Pain

Summary: the aim of this study is to answer the questions below; 1. is there a difference between patients with lumbar radiculopathy suffering from radicular pain and healthy subjects in terms of static and dynamic postural stability? 2. is there a relationship between postural stability and the neuropathic characteristics of radicular pain?

patients presenting to our outpatient clinic with radicular pain and mri findings associated with radiculopathy will be tested for static and dynamic postural stability. patient demographics, pain intensity, neuropathic pain scores, and level of disability will also be recorded. the demographic data and postural stability scores will also be collected for the control subjects. differences between the patient and control groups in terms of postural stability parameters will be sought. in addition, the relationship between the variables representing balance in the patient group and the neuropathic pain score and disability will be investigated.

Eligibility criteria:
inclusion criteria: * having radicular pain due to lumbar disc herniation. * root compression on the dominant side on imaging. * root compression at no more than two levels. * radicular pain with at least 3 points on a numerical rating scale. exclusion criteria: * no radicular pain despite root compression on imaging. * midline disc herniation or root compression on the nondominant side. * radicular pain on the non-dominant side. * treatment with neuropathic pain medication or psychotropic medication. * loss of muscle strength on clinical examination. * evidence of lower extremity atrophy, joint contractures, shortening of limbs, or similar disabilities. * presence of vision loss, vestibular or neurological disorders that may cause balance disorders.
sacral neuromodulation and faecal incontinence and its unknown effect on the external anal sphincter

Conditions: Fecal Incontinence

Summary: this innovative project aims to investigate structures and morphology of the external anal sphincter (eas) as well as the impact of sacral neuromodulation (snm) on the eas morphology and biochemistry among patients with faecal incontinence (fi). snm is a well implemented treatment for fi and consist of electrical stimulation of sacral nerve roots to promote continence and may even contribute to total continence. it has shown a positive effects on both short- and long-term. the biologic effect of snm on eas is unknown. the aim is to investigate the effect of snm on eas morphology, function, and biochemistry to help physicians and researchers to understand the underlying mechanisms of snm and the anal sphincter complex to further improve and optimize treatment methods for patients with fi. the research project consists of three phases. the first phase includes biopsies from the eas among patients with no previous history of fi. these patients have been diagnosed with rectal cancer and will undergo surgery with abdominoperineal excision. the second phase includes patients diagnosed with fi and subject for implantation of snm for treatment of fi. prior to implantation of snm all patients will have been examined with 3d endo-anal ultrasound and anorectal manometry as well as answered questionnaires targeting general health, bowel dysfunction and fi. a biopsy of the superficial portion of the eas is retrieved under local anaesthesia in connection to the test period for implantation of the snm device. the last phase, phase three, includes 3d endo-anal ultrasound, anorectal manometry, and a second biopsy of the eas twelve months after implantation with snm. the histopathological analysis in all the three phases will include general morphology, distribution of cell nuclei, satellite cells, muscle fiber type, neural structures and connective tissue.


Eligibility criteria:
phase 1 inclusion criteria: * ≥ 18 years of age * male or female * diagnosed with rectal cancer and receive treatment with abdominoperineal resection * signed an informed consent exclusion criteria: * previous diagnosis of fi * unable to speak and/or read swedish to ensure informed consent * tumour involving the sphincter complex or is in close connection phase 2 and 3 inclusion criteria: * diagnosed with fi and will receive treatment with sacral neuromodulation * male or female * signed an informed consent exclusion criteria: * unable to speak and/or read swedish to ensure informed consent

Keywords: fecal incontinence sacral neuromodulation surgery pathology proctology quality of life health status
interventional cryotherapy for the eradication of benign airway disease ("ice the bad")

Conditions: Lung Diseases, Obstructive; Sarcoidosis; Wegener's Granulomatosis; Rhinoscleroma; Recurrent Respiratory Papillomatosis

Summary: the purpose of this study is to evaluate the safety, effectiveness, and side effects of the cryospray ablationtm system (cryospray ablationtm, "csa" or "cryospray therapy") to treat benign airway disease in the lung using liquid nitrogen sprayed through a catheter via flexible fiber optic bronchoscopy (ffb)

the proposed study is a single center pilot study consisting of up to 10 subjects with benign airway disease. treatment dosimetry will be up to 4, 5-second spray cycles. subjects will have initial cryospray treatment at day 0. subjects will undergo repeat bronchoscopy in the first three to seven days after the initial treatment, to check for mucosal sloughing and to reassess luminal patency of the airway. subjects may undergo up to one bronchoscopy per week with csa therapy for a total of four (4) treatments in the first month. if they present with symptoms thereafter, then a repeat bronchoscopy will be performed; if luminal obstruction is noted, then the subject will begin the treatment protocol again. if disease exists bilaterally, only one side will be sprayed initially.

Eligibility criteria:
inclusion criteria: * 18 years of age * deemed a candidate for cryotherapy based on physician physical or medical history review * deemed operable based on institutional criteria. exclusion criteria: * pregnant or nursing * planning to sire a child while enrolled in the study * known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines. * refusal or inability to give consent. * concurrent chemotherapy. * prior radiation therapy which involved the any area between the vocal chords and the diaphragm * medical contraindication or potential problem that would preclude study participation * concurrent participation in other experimental studies uncontrolled coagulopathy or bleeding diathesis serious medical illness, including: * uncontrolled congestive heart failure * uncontrolled angina * myocardial infarction * cerebrovascular accident within 6 months prior to study entry

Keywords: benign airway disease airway injury sarcoidosis wegener's granulomatosis rhinoscleroma recurrent respiratory papillomatosis(rrp)
trial for the treatment of acute asthma in wheezy pre-school aged children

Conditions: Asthma

Summary: to determine if treatment of pre-school children with a history of wheeze who present to an emergency department with an acute wheezing episode with azithromycin for 5 days will resolve their symptoms more quickly, will require less short acting beta agonist (saba), and allow these children to remain symptom free for a longer period of time.


Eligibility criteria:
inclusion criteria: * 12-60 months * wheeze on auscultation exclusion criteria: * antibiotic use in the past 30 days * macrolide allergy * underlying medical condition * significant co-morbidities * current enrollment * language barrier or no access to phone for follow up

Keywords: pre-school child wheezy episode
botulinum toxin injection for preventing secondary atrial fibrillation in patient with supra-ventricular tachyarrythmias

Conditions: Supra-ventricular Tachyarrhythmias

Summary: the investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, rfa versus rfa plus botulinum toxin injection, in patients with supra-ventricular tachyarrhythmias. results were assessed with the use of an implanted monitoring device (imd).


Eligibility criteria:
inclusion criteria: * atrial flutter, av nodal re-entry tachycardia, focal atrial tachycardia, wpw syndrome * secondary atrial fibrillation exclusion criteria: * congestive heart failure * lv ejection fraction \< 35% * left atrial diameter \> 60 mm
pilot study person-centred tablet intervention

Conditions: Dementia; Mobile Applications; Computers; Neurological Rehabilitation; Activities of Daily Living

Summary: first evaluation of findmyapps, a tablet intervention consisting of a selection tool for usable apps for self-management and meaningful activities and a training that supports informal carers to help people with dementia to learn how to use the tablet and the tool.

testing the feasibility and mechanism of impact of findmyapps, a tablet intervention consisting of a selection tool to help persons with dementia find usable apps for self-management and meaningful activities and a training that supports informal carers to employ errorless learning principles to help people with dementia to learn how to use the tablet and the tool. an exploratory pilot randomized controlled trial was carried out with a mixed-methods design. twenty persons with mild dementia and carer dyads were randomly assigned to the findmyapps group (n = 10) that used the findmyapps training and selection tool, or a control condition that just got a tablet (n = 10). after informal carers had received the training, the dyads in the experimental group started with the three-month intervention. pre and post-test measurements consisted of questionnaires and post-test semi-structured interviews.

Eligibility criteria:
inclusion criteria: * eligible dyads had to be community dwelling. * persons with dementia had mild cognitive impairment or mild dementia with a score of 3 to 4 on the global deterioration scale (gds; 45), with or without a confirmed diagnosis. * availability of an informal carer or volunteer to provide support. exclusion criteria: * participation in another intervention trial * severe visual and/or physical impairment.

Keywords: medical research framework hand-held touchscreen devices self-management meaningful activities
harnessing telemedicine to improve alcohol use disorder outcomes in primary care patients

Conditions: Substance Use Disorders; Substance Use; Substance Dependence

Summary: the purpose of this trial is to test new programs to see if they might help people manage their health and health behaviors related to alcohol use and well-being. the program sessions focus on getting to know what's important to the participants, reviewing or setting goals, and using different skills and behaviors to better manage health. the trial will help the study team learn about ways to deliver health information in a way that is useful and interesting. this research will take place remotely (e.g., zoom, facetime, phone) and participants will be randomized to the telehealth (teletx) group intervention or the enhanced usual care (euc) control group. both groups will be asked to have follow-up visits up to 12 months from the baseline visit.


Eligibility criteria:
inclusion criteria: * current diagnostic and statistical manual (dsm) -5 alcohol use disorder (aud) based on alcohol symptom checklist * an average of 3 or more drinking days per week for the past 30 days * have regular access to a device with video capabilities or a phone to use for study related calls exclusion criteria: * inability to speak or understand english * conditions that preclude informed consent or understanding of assessment or intervention content * past 90-day aud psychotherapy treatment, * at elevated risk for complicated alcohol withdrawal * past-year drug injection.

Keywords: telehealth cognitive behavioral therapy psychoeducation motivational interviewing alcohol consumption
the treatment of bartholin´s cyst or abscess with silver nitrate

Conditions: Bartholin´s Cyst

Summary: silver nitrate treatment of bartholin's cyst or abscess will be compared to marsupialization treatment. it is expected that silver nitrate treatment is effective, simple, inexpensive and the least anaesthetic requiring procedure, which can easily be carried out in the outpatient setting.

background and objective: bartholin gland cysts and abscesses are common problems in women of reproductive age. the traditional treatment of bartholin´s cyst or abscess is marsupialization, which has disadvantages, such as pain of long duration, scarring, risk of general anaesthesia and risk of recurrence. in the present study we use silver nitrate in the treatment of bartholin's cyst or abscess and compare to marsupialization. we expect lower healing time, lower recurrence rate and less pain with the silver nitrate treatment. methods and materials: 30 patients with bartholin´s cyst or abscess will be investigated. it is prospective randomized study. the silver nitrate treatment is performed under local anaesthesia on an outpatient basis. a simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. a crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity. the standard marsupialization treatment is performed under general anaesthesia.

Eligibility criteria:
inclusion criteria: * women with a age of 18-60 years * should read and understand danish * all women inclusive pregnant should have a bartholins cyst or abscess exclusion criteria: * subject who cannot give written informed consent

Keywords: silver nitrate marsupialisation
emerging from the haze for gynecologic cancer survivors

Conditions: Gynecologic Neoplasms; Cognition Disorders

Summary: at cedars-sinai medical center, the investigators have developed a novel curriculum for a 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled emerging from the haze™ (haze). each series meets once a week for 2-2.5 hours for 6 weeks. the objective of this study is to quantify the impact of a trainee-taught emerging from the haze course on gynecologic cancer survivors' self-report of cognitive changes based on the change of fact-cog score.


Eligibility criteria:
inclusion criteria: * diagnosis of any stage gynecologic cancer including ovarian, uterine/endometrial, cervical, vulvar, and vaginal cancer * treated with chemotherapy solely or in combination with surgery, radiation, and/or hormonal therapy * female, age ≥ 18 years. * fact-cog score \< 59 on the pci sub scale * eligible after 2 months (60 ±5 days) of completing all their active cancer treatment with the exception of long-term hormonal treatments * subjective complaint of cognitive concerns at time of enrollment * must be able to understand and communicate proficiently in english * ability to understand and the willingness to sign a written informed consent. * agree to complete study surveys exclusion criteria: * patients who have significant personality disorders or unstable psychiatric disorders (including active major depression, substance abuse, psychosis or bipolar disorder) as assessed by the interviewing clinician * patients with known brain metastases, history of brain metastases or radiation to the brain. * patients with a history of stroke or other pre-existing neurological condition that may contribute to cognitive dysfunction. * non-english speakers * receiving treatment for another malignancy other than breast cancer * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, chronic anemia, uncontrolled hypothyroidism, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
anthocyanin extract and phospholipid curcumin in colorectal adenoma

Conditions: Colorectal Adenoma; Risk Reduction

Summary: it has been shown that curcumin and cyanidin-3-glucoside (c3g) have anticancer effects. in this clinical trial we compare the affect of their combination vs placebo in a four weeks intervention before endoscopic polypectomy.

colonic adenomatous polyps are pre cancer lesions and are used as intermediate markers for testing agents with potential cancer prevention. meriva© is a bioavailable form of curcumin, a polyphenolic compound obtained from turmeric (curcuma longa l.) endowed with anti-inflammatory, antioxidant and antitumor effects. in vivo data indicate that curcumin formulated with phosphatidylcholine furnishes higher blood levels of parent agent than natural curcumin. mirtoselect©, an anthocyanin mixture from bilberry containing isolated cyanidin-3-glucoside (c3g), the most abundant anthocyanin in diet, prevents intestinal adenoma formation in the apc(min) mouse model. the investigators hypothesize that the combination of both agents will decrease the expression of proteins involved in colon tumorigenesis relative to placebo. the change of biomarker expression between pre-treatment biopsy and post-treatment endoscopic resection in the target adenoma and the normal rectal mucosa will be the response measures. the primary response measure is the change of immunohistochemical (ihc) expression of β-catenin in adenomatous tissue and normal rectal mucosa. secondary response measures are the changes of ihc nuclear factor-kβ (nfkβ), cell proliferation by ki-67 labeling index and apoptosis by p53 in adenomatous and adjacent normal mucosa. the study design is a phase ii, randomized, double blind, placebo controlled, window of opportunity trial of the combination of mirtoselect 1 gr/day+meriva 1 gr/day or placebo. subjects with histological confirmation of colorectal adenomatous polyps \>1 cm not suitable to immediate complete removal will be enrolled in a 4-week intervention trial before endoscopic polypectomy. the demonstration of a biological activity of the two agent combination may provide the rationale for a phase iii trial aimed at reducing the risk of colon cancer in high risk subjects.

Eligibility criteria:
inclusion criteria: * subjects with colorectal adenomatous polyps greater than 1 cm in maximum diameter not suitable to immediate complete removal; * normal renal and hepatic function; * who performance status=0; exclusion criteria: * presence of hyperplastic polyps and/or flat adenomas; * subjects with pre-existing colorectal cancer; * presence of carcinomatous tissue in adenoma;